Ptc Therapeutics, Inc. Earnings

Ptc Therapeutics, Inc.’s revenue fell -22.75% since last year same period to $164.68Mn in the Q4 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated -21.96% fall in its revenue since last 3-months.

Ptc Therapeutics, Inc.’s net profit fell -104.85% since last year same period to $-134.97Mn in the Q4 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated -949.05% fall in its net profits since last 3-months.

Ptc Therapeutics, Inc.’s net profit margin fell -165.17% since last year same period to -81.96% in the Q4 2025. On a quarterly growth basis, Ptc Therapeutics, Inc. has generated -1187.92% fall in its net profit margins since last 3-months.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.63 - a -144.31% fall from last quarter’s estimates.

Ptc Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at -0.63.

Ptc Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Ptc Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.